PAODPeripheral Arterial Occlusive Disease
PAODPeripheral Arterial Obliterative Disease (biomedicine)
PAODPost Academisch Onderwijs Diergeneeskunde (Dutch: Postgraduate Education Veterinary Medicine; Merelbeke, Belgium)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
In present study we found more number of the cases of PAOD positive for stenosis with CDUS than CTA, in comparison to the study conducted by Kayhan A et al.
amputation of the leg with advanced PAOD. Trying anything and everything, the man came in for naturopathic treatment, but specifically declared himself unwilling to change anything about his unhealthful lifestyle.
The recommendation follows a CHMP's review of the safety and effectiveness of buflomedil concluding that the adverse effects, mainly the risks of cardiac and neurological side effects, are bigger than the limited positive impact in PAOD therapy.
Risk factors for PAOD in the general population include advancing age, hypertension, smoking, diabetes, and coronary artery disease (O'Hare & Johansen, 2001).
Summers, chairman and CEO of Endovasc commented that, "Our clinical trials for Liprostin(TM) are being conducted to treat peripheral arterial occlusive disease (PAOD) patients in cases involving critical limb ischemia; but it is obvious that our goal is to progress to treating coronary artery disease as soon as possible." Test results from a previously conducted study for safety in pig hearts using single bolus of up to 2.5 mg of Liprostin(TM), was administered at the time of angioplasty in models having blocked arteries, proved that Liprostin(TM) was safe in treating restenosis (re-blockage) in coronary arteries and that the treated arteries showed only an 8% rate of restenosis at 28 days.
NEED FOR THE STUDY: Peripheral vascular disease (PVD), commonly referred to as peripheral arterial disease (PAD) or peripheral artery occlusive disease (PAOD), refers to the obstruction of arteries of the limbs.
In summary, infusion therapy with [PGE.sub.1] in patients with peripheral arterial occlusive disease (PAOD) reduces thrombin formation and results in a decrease of fibrin degradation.
Peripheral arterial occlusive disease (PAOD) was present in 124 patients, 59 of whom suffered from rest pain or gangrene.
On the other hand Digital subtraction-angiography (DSA) is also a commonly used modality for diagnosis of PAOD. [5] It has advantages like it can detect slow flow of small vessels and collaterals much better when compared to ultrasound, percentage of stenosis and occlusion is better determined and it is not operator dependent, provides better anatomical details and deep seated arteries like infra genicular arteries are much better visualized.
[ClickPress, Thu Sep 18 2014] Global Markets Direct's, 'Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2014', provides an overview of the Peripheral Artery Occlusive Disease (PAOD)'s therapeutic pipeline.